Avax Techs Inc (AVXT) 0.0067 $AVXT
AVAX Technologies Announces Results Of Its OVAX, Ovarian Cancer Vaccine, Phase 1/2 Clinical Trial In Patients With Relapsed Stage III Or IV Ovarian Cancer.
PR Newswire - Tue Jan 26, 5:08PM CST
AVAX Technologies, Inc. (USOTC: AVXT), a pioneer in personalized cancer vaccines, today announced the results of its Phase 1/2 OVAX study in patients with platinum resistant relapsed Stage III or IV Ovarian Cancer. The overall design is a Phase I/II, double-blind, three-dose regimen, multi-centered, trial in patients with stage III or stage IV ovarian carcinoma who have undergone de-bulking followed by intra-peritoneal chemotherapy.
AVAX Technologies, Inc. Announces the Appointment of Chief Executive Officer
PR Newswire - Mon Oct 19, 7:00AM CDT
AVAX Technologies, Inc. (USOTC:AVXT), a pioneer and leader in the clinical development and production of autologous cancer immunotherapy vaccines, is pleased to announce the expansion of its executive team with the appointment of Adele Sommerfeld as Chief Executive Officer. Ms. Sommerfeld joins the AVAX management team with a breadth of experience within the biotechnology industry, spanning over 25 years. She brings significant experience across functional areas including biotechnology equity financing transactions, corporate strategy, strategic partnering, and business development. Ms. Sommerfeld has a MBA and M.Sc. in Molecular Genetics from the University of Toronto. "I am excited about the prospects and potential of AVAX as we move forward in re-launching the company's significant achievements back into the mainstream. As a pioneer in the immuno-oncology arena, AVAX has successfully moved two vaccines into clinical development, has built a vaccine production facility, and has a patented Autologous Cell vaccine technology platform. Furthermore, the enhanced management team will continue to focus on closing the previously announced $45 million financing, advancing AVAX's proprietary cancer immunotherapy vaccines through clinical and commercial development, and developing future next generation products that leverage off of the Company's proven AC technology platform and intellectual property," said Adele Sommerfeld.
AVAX Technologies Announces Results Of Its OVAX, Ovarian Cancer Vaccine, Phase 1/2 Clinical Trial In Patients With Relapsed Stage III Or IV Ovarian Cancer.
PR Newswire - Tue Jan 26, 5:08PM CST
AVAX Technologies, Inc. (USOTC: AVXT), a pioneer in personalized cancer vaccines, today announced the results of its Phase 1/2 OVAX study in patients with platinum resistant relapsed Stage III or IV Ovarian Cancer. The overall design is a Phase I/II, double-blind, three-dose regimen, multi-centered, trial in patients with stage III or stage IV ovarian carcinoma who have undergone de-bulking followed by intra-peritoneal chemotherapy.
AVAX Technologies, Inc. Announces the Appointment of Chief Executive Officer
PR Newswire - Mon Oct 19, 7:00AM CDT
AVAX Technologies, Inc. (USOTC:AVXT), a pioneer and leader in the clinical development and production of autologous cancer immunotherapy vaccines, is pleased to announce the expansion of its executive team with the appointment of Adele Sommerfeld as Chief Executive Officer. Ms. Sommerfeld joins the AVAX management team with a breadth of experience within the biotechnology industry, spanning over 25 years. She brings significant experience across functional areas including biotechnology equity financing transactions, corporate strategy, strategic partnering, and business development. Ms. Sommerfeld has a MBA and M.Sc. in Molecular Genetics from the University of Toronto. "I am excited about the prospects and potential of AVAX as we move forward in re-launching the company's significant achievements back into the mainstream. As a pioneer in the immuno-oncology arena, AVAX has successfully moved two vaccines into clinical development, has built a vaccine production facility, and has a patented Autologous Cell vaccine technology platform. Furthermore, the enhanced management team will continue to focus on closing the previously announced $45 million financing, advancing AVAX's proprietary cancer immunotherapy vaccines through clinical and commercial development, and developing future next generation products that leverage off of the Company's proven AC technology platform and intellectual property," said Adele Sommerfeld.
